BeiGene: Revenue in the first half of 2026 was 22.22 billion yuan, with a year-on-year net profit increase of 627.1%.

Beijing BGI announced that in the first half of 2026, the company's total operating revenue reached 22.22 billion yuan, an increase of 26.8% year-on-year; the net profit attributable to the owners of the parent company was 3.271 billion yuan, a year-on-year increase of 627.1%. The growth in product revenue was mainly attributed to the sales increase of licensed products from Baitai and Amgen, as well as Bai Zean. In addition, the company announced an additional investment of $300 million to expand its R&D center in the United States and appointed three new board members.